Table 3.
Mean Annualized Percent Change in Bone Mineral Density by Anatomic Site in Primary and Sensitivity Analysis Models
| Spine | Femoral neck | Total hip | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary modela |
Sensitivity analysis modelb |
Primary modela |
Sensitivity analysis modelc |
Primary modela |
Sensitivity analysis modeld |
|||||||
| Estimate | (95% CI) | Estimate | (95% CI) | Estimate | (95% CI) | Estimate | (95% CI) | Estimate | (95% CI) | Estimate | (95% CI) | |
| Non-user (n = 1605) | −0.61 | (−0.67, −0.55) | −0.58 | (−0.63, −0.52) | −0.46 | (−0.51, 0.42) | −0.45 | (−0.50, −0.40) | −0.32 | (−0.36, 0.27) | −0.31 | (−0.35, −0.26) |
| H2RA user (n = 185) | −0.54 | (−0.68, −0.39) | −0.51 | (−0.65, −0.37) | −0.44 | (−0.55,−0.33) | −0.45 | (−0.56, −0.34) | −0.37 | (−0.47, −0.26) | −0.36 | (−0.47, −0.25) |
| PPI user (n = 207) | −0.53 | (−0.68, −0.38) | −0.48 | (−0.62, −0.33) | −0.43 | (−0.54,−0.32) | −0.41 | (−0.53, −0.29) | −0.41 | (−0.52, −0.29) | −0.38 | (−0.49, −0.27) |
a
Main model adjusted for age, menopausal status, site, race, and BMI.
b
Spine MV model = primary model variables, smoking, diabetes, cancer, osteoporosis, vasomotor symptoms, hormone therapy, and bisphosphonate and thiazide diuretic use.
c
Femoral neck MV model = primary model variables, income, education level, physical activity, cancer, diabetes, hormone therapy, and bisphosphonate and thiazide diuretic use.
d
Total hip MV model = primary model variables, education level, physical activity, cancer, diabetes, hormone therapy, and bisphosphonate and thiazide diuretic use.